Haemonetics Announces the Release of NextGen DMS 4

BRAINTREE, Mass., Dec. 8, 2016

The launch of NextGen DMS 4 improves core features and introduces innovations aligned with the industry focus including: reducing the cost per liter of plasma collected, enhancing quality and regulatory compliance and leveraging data to analyze and improve plasma center operations.

The release of NextGen DMS 4 will enable automated donor address verification, paperless intake and annual medical assessment and will extend capabilities of the donor floor mobile application to streamline phlebotomy documentation. Additionally, new quality checklists used by staff at key processing steps will  help collection centers quickly and reliably follow their standard operating procedures.

"NextGen DMS 4 is an important achievement on our path to the plasma center of the future; a future that will deliver significant efficiency gains in the collection process, resulting in tangible value to our customers," said Tom McCurdy, President, Global Plasma. "Our solutions are used in plasma collections worldwide to help deliver quality, life-changing therapies. We are proud of our mission and excited about this release for our customers," he said.

About Haemonetics®
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative hematology products and solutions for our customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, please visit http://www.haemonetics.com/

Investor Contact
Gerry Gould, VP, Investor Relations
(781) 356-9402
gerry.gould@haemonetics.com    

Media Contact
Sandra Jesse, EVP, Chief Legal Officer
(781) 356-9253
sandra.jesse@haemonetics.com